AstraZeneca Submits Symbicort For Asthmatics As Young As Six
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator touts inhaler's safety profile.
You may also be interested in...
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting
AstraZeneca Wants COPD Label For Symbicort
Newly reported trials prove safety and efficacy, company says.